134914-97-9

Basic information

• Product Name: 2-Methyl-4-(tributylstannyl)pyridine
• Synonyms: 2-Methyl-4-(tributylstannyl)pyridine;Tributyl-(2-MethylpyridiN-4-Yl)Stannane
• CAS NO: 134914-97-9
• Molecular Formula: C18H33NSn
• Molecular Weight: 382.17132
• Product Categories: Stannanes
• Mol File: 134914-97-9.mol

Chemical Properties

• Boiling Point: 391.9°C at 760 mmHg
• Flash Point: 190.8°C
• Appearance: /
• Vapor Pressure: 5.39E-06mmHg at 25°C
• CAS DataBase Reference: 2-Methyl-4-(tributylstannyl)pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Methyl-4-(tributylstannyl)pyridine(134914-97-9)
• EPA Substance Registry System: 2-Methyl-4-(tributylstannyl)pyridine(134914-97-9)

Safety Data

• Hazardous Substances Data: 134914-97-9(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
2-methyl-4-(tributylstannyl)pyridine is used as a reagent for the functionalization of aromatic compounds, leveraging the tributylstannyl group as a useful leaving group in various reactions, which allows for the attachment of new functional groups onto the pyridine ring.
Used in Preparation of Organometallic Reagents:
2-methyl-4-(tributylstannyl)pyridine is utilized in the preparation of organometallic reagents, which are essential in various chemical reactions and processes, contributing to the advancement of synthetic chemistry.
Used in Pharmaceutical and Agrochemical Synthesis:
2-methyl-4-(tributylstannyl)pyridine is employed in the synthesis of pharmaceuticals and agrochemicals, where its unique structure and reactivity contribute to the development of new and effective compounds for medical and agricultural applications.
However, it is important to note that due to the toxic properties associated with the tributylstannyl group, the use of 2-methyl-4-(tributylstannyl)pyridine is restricted in certain applications to ensure safety and environmental considerations.

InChI:InChI=1/C6H6N.3C4H9.Sn/c1-6-4-2-3-5-7-6;3*1-3-4-2;/h3-5H,1H3;3*1,3-4H2,2H3;/rC18H33NSn/c1-5-8-13-20(14-9-6-2,15-10-7-3)18-11-12-19-17(4)16-18/h11-12,16H,5-10,13-15H2,1-4H3

Upstream product

• 22282-99-1 4-bromo-2-methylpyridine 
• 1461-22-9 tributyltin chloride 

Downstream Products

• 1243244-44-1 N-(5-(pyrazin-2-yl)pyridin-2-yl)-2-(4-(pyridazin-4-yl)-3-(trifluoromethyl)phenyl)acetamide 
• 1243244-84-9 N-(5-(4-acetylpiperazin-1-yl)pyridin-2-yl)-2-(3-methyl-4-(2-methylpyridin-4-yl)phenyl)acetamide 
• 1243244-93-0 N-(5-(4-acetylpiperazin-1-yl)pyridin-2-yl)-2-(3-fluoro-4-(2-methylpyridin-4-yl)phenyl)acetamide 
• 1243246-00-5 2-(3-methoxy-4-(2-methylpyridin-4-yl)phenyl)acetic acid 
• 1243245-61-5 N-(5-(4-acetylpiperazin-1-yl)pyridin-2-yl)-2-(4-cyano-3-(2-methylpyridin-4-yl)phenyl)acetamide 
• 1243245-80-8 tert-butyl 2-(3-cyano-4-(2-methylpyridin-4-yl)phenyl)acetate 

Relevant articles and documents

Design, synthesis, and evaluation of potent Wnt signaling inhibitors featuring a fused 3-ring system

The Wnt signaling pathway is a critical developmental pathway which operates through control of cellular functions such as proliferation and differentiation. Aberrant Wnt signaling has been linked to the formation and metastasis of tumors. Porcupine, a member of the membrane-bound O-acyltransferase family of proteins, is an important component of the Wnt pathway. Porcupine catalyzes the palmitoylation of Wnt proteins, a process needed for their secretion and activity. Here we report a novel series of compounds obtained by a scaffold hybridization strategy from a known porcupine inhibitor class. The leading compound 59 demonstrated subnanomolar inhibition of Wnt signaling in a paracrine cellular assay. Compound 59 also showed excellent chemical, plasma and liver microsomal stabilities. Furthermore, compound 59 exhibited good pharmacokinetic profiles with 30% oral bioavailability in rat. Collectively, these results strongly support further optimization of this novel scaffold to develop better Wnt pathway inhibitors.

Compounds and Their Use for Treatment of Amyloid Beta-Related Diseases

The present invention relates to novel compounds of formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising said compounds, processes for making said compounds, and their use as medicaments for treatment and/or prevention of Aβ-related diseases.

NOVEL SULFONYL DERIVATIVES

Sulfonyl derivatives represented by the following general formula (I): Q1-Q2-T1-Q3-SO2-QA and drugs containing the same (wherein Q1 is an optionally substituted, saturated or unsaturated, five- or six-membered cyclic hydrocarbon group, a five- or six-membered heterocyclic group, or the like; Q2 is a single band, oxygen, sulfur, C1-C6 alkylene or the like; QA is optionally substituted arylalkenyl, heteroarylalkenyl or the like; and T1 is carbonyl or the like). These compounds have potent FXa-inhibitory effects and promptly exert satisfactory and persistent antithrombotic effects through oral administration, thus being useful as anticoagulant agents little accompanied with side effects.